Development of β-lactamase-mediated resistance to penicillin in middle-ear isolates of moraxella catarrhalis in finnish children, 1978–1993

Clinical Infectious Diseases

Volumn 21, Issue 5, 1995, Pages 1193-1196

  Nissinen, Antti ^a,b,c,d,e,f   Gönroos, Paul ^a,b,c,d,e,f   Huovinen, Pentti ^a,b,c,d,e,f   Herva, Elja ^a,b,c,d,e,f   Katila, Marja Leena ^a,b,c,d,e,f   Klaukka, Timo ^a,b,c,d,e,f   Kontiainen, Sirkka ^a,b,c,d,e,f   Liimatainen, Oili ^a,b,c,d,e,f   Oinonen, Sinikka ^a,b,c,d,e,f   Mäkelä, P Helena ^a,b,c,d,e,f  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

^e Aurora Hospital   (Finland)

^f Aurora Hospital ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFACLOR; CEFALOTIN; COTRIMOXAZOLE; ERYTHROMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; HAEMOPHILUS INFLUENZAE TYPE A; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; OTITIS MEDIA; PENICILLIN RESISTANCE; PREVALENCE; PRIORITY JOURNAL;

ANTIBIOTICS, LACTAM; BETA-LACTAMASES; CHILD, PRESCHOOL; FINLAND; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; INFANT, NEWBORN; MORAXELLA (BRANHAMELLA) CATARRHALIS; NEISSERIACEAE INFECTIONS; OTITIS MEDIA; PENICILLIN RESISTANCE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0028857942     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/21.5.1193     Document Type: Article

References (26)

1. Karma P, Virtanen T, Pukander J, et al. Branhamella catarrhalis in acute otitis media. Acta Otolaryngol 1985;99:285-90.
2. Van Hare GF, Shurin PA, Marchant CD, et al. Acute otitis media caused by Branhamella catarrhalis: biology and therapy. Rev Infect Dis 1987;9:16-27.
3. Bluesone CD, Stephenson JS, Martin LH. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992; 11:S7-11.
4. Malmvall BE, Brorson JE, Johnsson J. In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother 1977;3:374-5.
5. Jorgensen JH, Doem GV, Maher LA, Howell AW, Redding JS. Antimicro bial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in United States. Antimicrob Agents Chemother 1990;34:2075-80.
6. Fung CP, Powell M, Seymor A, Yuan M, Williams JD. The antimicrobial susceptibility of Moraxella catarrhalis isolates in England and Scotland in 1991. J Antimicrob Chemother 1992;30:47-55.
7. Doem GV, Tubert TA. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother 1988;32:259-61.
8. Richards J. Evaluation of a rapid method for identifying Branhamella catarrhalis. J Clin Pathol 1988;41:462-4.
9. Kjallander J, Myrback KE. A simple test for penicillinase-production. Acta Pathol Microbiol Scand 1964; 61:494.
10. Bryan LE, Godfrey AJ. β-Lactam antibiotics: mode of action and bacterial resistance. In: Lorian V, ed. Antibiotics in laboratory medicine. 3rd ed. Baltimore: Williams & Wilkins, 1991:599-664.
11. National Committee for Clinical Laboratory Standards. Methods for dilu tion antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Document M7-A2. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1990.
12. Olsson-Liljequist B, Burman L, Kallings I, Swedish Respiratory Study Group. Antimicrobial susceptibility of upper respiratory tract pathogens in Sweden: a seven-year follow-up study including Loracarbef. Scand J Infect Dis 1992;24:485-93.
13. Brown BA, Wallace RJ, Flanagen CW, Wilson RW, Luman JI, Redditt SD. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother 1989; 33:1631-3.
14. Riley TV. Antimicrobial resistance in Branhamella catarrhalis. J Antimi crob Chemother 1988;21:147-50.
15. Eliasson I, Kamme C. Characterization of the plasmid-mediated β-lacta mase in Branhamella catarrhalis, with special reference to substrate affinity. J Antimicrob Chemother 1985;15:139-49.
16. Fung CP, Yeo SF, Livermore DM. Susceptibility of Moraxella catarrhalis isolates to /?-lactam antibiotics in relation to β-lactamase pattern. J Antimicrob Chemother 1994;33:215-22.
17. Oberlin JA, Hyslop DL. Cefaclor treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis. Pediatr Infect Dis J 1990;9:41-4.
18. Wallace RJ, Steingrube VA, Nash DR, et al. BRO β-lactamases of Branha mella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother 1989;33:1845-54.
19. Maryama S, Yoshioka H, Fujita K, Takimoto M, Satake Y. Sensitivity of group A streptococci to antibiotics. Am J Dis Child 1979; 133: 143-5.
20. Phillips G, Parrat D, Orange GV, Harper I, McEvan H, Young N. Erythro mycin resistant Streptococcus pyogenes. J Antimicrob Chemother 1990;25:723-4.
21. Seppala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992;326:292-7.
22. Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28(suppl):31-8.
23. Ohana N, Keness J, Vemer E, Raz R, Rozeman D, Zuckerman F. Skin- isolated, community acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin. J Am Acad Dermatol 1989;21: 544-6.
24. Rosdahl VT, Weth H, Jensen K. Antibiotic susceptibility and phage-type patterns of Staphylococcus aureus strains isolated from patients in general practice compared to strains from hospitalized patients. Scand J Infect Dis 1990;22:315-20.
25. Marton A. Pneumococcal antimicrobial resistance: the problem in Hun gary. Clin Infect Dis 1992;15:106-11.
26. Koomhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Strepto coccus pneumoniae: a South African perspective. Clin Infect Dis 1992;15:84-94.